Integer Holdings Corporation
Medical device CDMO for cardiac devices
General Operator
About the job
- A Leaving Certificate or equivalent standard is required.
- Good oral and written communication skills are required.
- Basic personal computer skills are advantageous.
- A good timekeeping, attendance, and performance record is required.
- The employee must communicate effectively with people inside and outside the department while presenting a professional, friendly, and courteous image.
- The employee must be conscientious, attentive to detail, quality-focused, and able to follow standard operating procedures and job breakdown sheets with a diligent approach to documentation.
- The employee must be well organized and have good interpersonal skills.
- The employee must comply with gowning procedures and quality standards and good manufacturing practices for production in cleanroom areas.
- Perform all duties assigned by the Supervisor.
- Adhere to relevant standard operating procedures and job breakdown sheets.
- Complete and comply with all required documentation.
- Carry out asset care on equipment and set up machines in job-specific areas.
- Participate in continuous improvement projects.
- Help maintain a clean and safe working environment, including high standards of housekeeping and chemical control under 5S.
- Support the quality concepts and lean manufacturing system of Integer Ireland Limited.
- Comply with Integer Ireland Limited behavioral standards.
- Basic personal computer skills are advantageous.
About the company
Integer Holdings Corporation is a large medical device contract development and manufacturing organization (CDMO) that supports medical device makers in cardiac rhythm management, neuromodulation, and cardiovascular markets. It provides end-to-end services from design support to manufacturing, delivering components and finished subsystems such as implants, housings, electrodes, and batteries through its Greatbatch Medical, Lake Region Medical, and Electrochem brands. The company differentiates itself by its scale, breadth of capabilities across multiple medical specialties, established brand portfolio, and global manufacturing footprint that enable reliable, integrated supply. Its goal is to improve patients’ lives worldwide by helping customers bring safe and effective medical technologies to market.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Wilmington, Delaware
Founded
1940
Get referred to Integer Holdings Corporation
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 revenue hit $464.1 million, beating estimates despite weak medtech demand.
- Integer expects demand recovery after New Ross's July 27-August 10, 2026 shutdown.
- KKR plans new capacity, technology, and employee ownership after closing by year-end 2026.
What critics are saying
- Integer withdrew 2026 guidance on August 3, 2026, after KKR announced the buyout.
- Schall, Brown & Schwartz opened an August 23, 2026 fiduciary-duty investigation.
- Regulatory or stockholder rejection kills the KKR deal and leaves Integer's weak standalone outlook exposed.
What makes Integer Holdings Corporation unique
- Integer's R&D Velocity integrates design, prototyping, and manufacturing for complex medtech programs.
- Its 33-facility global network spans electrophysiology, neuromodulation, and structural heart.
- KKR's August 3, 2026, $5.7 billion bid validates Integer's scale and customer lock-in.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Adoption Assistance
Parental Leave
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Paid Holidays
Company News
Boussard & Gavaudan Gestion Sas bought a new position in Integer Holdings Corporation (NYSE:ITGR – Free Report) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 28,153 shares of the medical equipment provider’s stock, valued at approximately $2,597,000. Other institutional investors and hedge funds also […]
Healthcare stocks have returned 26.1% over the past six months, outperforming the S&P 500 by 13.1 percentage points. However, investors must remain cautious due to heavy regulation affecting earnings potential. Integer Holdings faces concerns with 6.1% annual revenue growth over two years, lagging healthcare peers. Its modest revenue base of $1.84 billion provides less fixed cost leverage than larger competitors. The company trades at $125.07 per share, or 18.6 times forward price-to-earnings. Evolent Health shows weak platform performance and declining returns on capital. Its high net-debt-to-EBITDA ratio of 7 times could force unfavourable capital raises if market conditions worsen. Shares trade at $4.15, representing 12.4 times forward price-to-earnings. Tenet Healthcare, operating hospitals and surgical centres across nine US states, emerges as the recommended healthcare investment.
Integer Holdings agreed to be acquired by private equity firm KKR in an all-cash deal valued at approximately $5.7 billion. The transaction values the medical technology company at $127 per share. Shares jumped 2.7% in afternoon trading, continuing a rally from the previous session when the stock surged over 20% following the announcement. The acquisition news overshadowed strong second-quarter results, where Integer posted an adjusted profit of $1.60 per share on $464.1 million in revenue, surpassing analyst estimates. Following the buyout announcement, Integer withdrew its previously issued financial guidance and cancelled its upcoming earnings conference call. Shares traded at $124.50, marking a new 52-week high.
KKR has agreed to acquire Integer Holdings Corporation, a medical device contract development and manufacturing organisation, in an all-cash transaction valued at approximately $5.7 billion. Integer stockholders will receive $127 per share, representing a 51.8% premium to the company's closing share price on 29 April 2026. The acquisition follows a comprehensive strategic review announced by Integer in April 2026. The Integer Board unanimously approved the agreement and recommends stockholder approval. KKR plans to invest in Integer's capacity, technology, innovation, and talent. The firm also intends to establish a broad-based employee ownership programme following the transaction's close, consistent with its approach across portfolio companies. The transaction is expected to close by year-end, subject to stockholder approval and regulatory clearances. Upon completion, Integer will become privately held and delist from the New York Stock Exchange.
Integer Holdings Corp. reported second-quarter net income of $23.6 million, or 69 cents per share. Adjusted earnings came to $1.60 per share, exceeding Wall Street expectations of $1.38 per share. The Plano, Texas-based medical device outsource manufacturer posted revenue of $464.1 million for the period, also beating analyst forecasts of $452.5 million. The results surpassed predictions from five analysts surveyed by Zacks Investment Research on both earnings and revenue metrics.